United States - English - NLM (National Library of Medicine)

viatrexx bio incorporated - carduus benedictus (30k), carduus marianus (30k), ceanothus americanus (6x), chelidonium majus (30k), chionanthus virginica (6x), choline (30k), coelliac plexus (8x, 200k), duodenum (30k), fumaric acid (30k), gall bladder (30k), inositol (30k), il 4 (10x, 200k), kalium sulfuricum (6x, 30k), liver (6x, 200k), lycopodium clavatum (30k), natrium oxalaceticum (30k), natrium pyruvicum (30k), natrium sulphuricum (6x, 30k), niacin (30k), pancreas (8x, 200k), spleen (6x, 200k), taraxacum (30k), vein (30k), vitamin - to help support the structure & function of the liver

United States - English - NLM (National Library of Medicine)

bioactive nutritional, inc. - milk thistle (unii: u946sh95ee) (milk thistle - unii:u946sh95ee), chelidonium majus (unii: 7e889u5rnn) (chelidonium majus - unii:7e889u5rnn), taraxacum officinale (unii: 39981fm375) (taraxacum officinale - unii:39981fm375), chionanthus virginicus bark (unii: s9y4b22u2e) (chionanthus virginicus bark - unii:s9y4b22u2e), quassia amara wood (unii: s5249q85hw) (quassia amara wood - unii:s5249q85hw), calcium sulfide (unii: 1mbw07j51q) (calcium sulfide - unii:1mbw07j51q), beef liver (unii: w8n8r55022) (beef - milk thistle 1 [hp_x] in 1 ml - for temporary relief of sour, bitter taste after eating, fullness and soreness over the liver, coated tongue, flatulence, and diarrhea alternating with constipation. for temporary relief of sour, bitter taste after eating, fullness and soreness over the liver, coated tongue, flatulence, and diarrhea alternating with constipation.

United States - English - NLM (National Library of Medicine)

bioactive nutritional, inc. - silybum marianum seed (unii: u946sh95ee) (silybum marianum seed - unii:u946sh95ee), chelidonium majus (unii: 7e889u5rnn) (chelidonium majus - unii:7e889u5rnn), taraxacum officinale (unii: 39981fm375) (taraxacum officinale - unii:39981fm375), chionanthus virginicus bark (unii: s9y4b22u2e) (chionanthus virginicus bark - unii:s9y4b22u2e), quassia amara wood (unii: s5249q85hw) (quassia amara wood - unii:s5249q85hw), beef liver (unii: w8n8r55022) (beef liver - unii:w8n8r55022), ceanothus americanus leaf (u - for temporary relief of sour, bitter taste after eating, fullness and soreness over the liver, coated tongue, flatulence, and diarrhea alternating with constipation. for temporary relief of sour, bitter taste after eating, fullness and soreness over the liver, coated tongue, flatulence, and diarrhea alternating with constipation.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 2.1 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 16.8 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 16.8 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 4.2 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 8.4 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 2.1 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 8.4 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.